SMMT

MKT CAP:$17B

Summit Therapeutics Inc.

Market Cap

$17B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$21.54+$4.02 (+22.95%)

Apr 24, 2026

Company Details

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile...

CEO

Robert W. Duggan

IPO Date

Mar 5, 2015

Website

www.summittxinc.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$1.1B

EPS (Diluted)

-$1.45

Free Cash Flow

-$324M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 7, 2026

PENDING

FY 2025

Feb 23, 2026

$0EPS -$1.44

Q4 2025

Feb 23, 2026

$0EPS -$0.29

Q3 2025

Aug 11, 2025

$0EPS -$0.31

Q2 2025

Aug 11, 2025

$0EPS -$0.76

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 21	$1M	$1M	-$19M
Q1 22	$250.0K	$250.0K	-$22M
Q2 22	$235.0K	$193.1K	-$13M
Q3 22	$220.0K	$220.0K	-$17M
Q4 22	$705	-$595.0K	-$20M
Q1 23	$0	$0	-$537M
Q2 23	$235.0K	-$236.0K	-$16M
Q3 23	$0	-$599.0K	-$20M
Q1 24	$0	-$27.0K	-$42M
Q2 24	$0	-$20.0K	-$60M
Q3 24	$0	-$20.0K	-$58M
Q4 24	$0	-$15M	-$66M
Q1 25	$0	-$25.0K	-$67M
Q2 25	$0	-$37.0K	-$568M
Q3 25	$0	-$42.0K	-$234M
Q4 25	$0	-$4.4K	$57M

Valuation

Quarter	P/S	P/E
Q3 21	322.6x	—
Q1 22	147.0x	—
Q2 22	54.9x	—
Q3 22	126.8x	—
Q4 22	2020.2x	—
Q1 23	2801.7x	—
Q2 23	3705.3x	—
Q3 23	5269.0x	—
Q1 24	11363.2x	—
Q2 24	24356.8x	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 21	-$24M	-$24M
Q1 22	-$19M	-$19M
Q2 22	-$19M	-$20M
Q3 22	-$9M	-$9M
Q4 22	$5M	$6M
Q1 23	-$13M	-$13M
Q2 23	-$29M	-$29M
Q3 23	-$15M	-$15M
Q1 24	-$30M	-$30M
Q2 24	-$33M	-$33M
Q3 24	-$30M	-$30M
Q4 24	-$49M	-$49M
Q1 25	-$61M	-$62M
Q2 25	-$67M	-$67M
Q3 25	-$95M	-$95M
Q4 25	-$100M	-$100M

Capital Expenditures

Quarter	CapEx
Q3 21	$4.0K
Q1 22	$361.0K
Q2 22	$293.0K
Q3 22	$20.0K
Q4 22	$994.4K
Q1 23	$53.0K
Q2 23	$20.0K
Q3 23	$53.0K
Q1 24	$4.0K
Q2 24	$62.8K
Q3 24	$58.0K
Q4 24	$14.2K
Q1 25	$422.0K
Q2 25	$12.7K
Q3 25	$71.2K
Q4 25	$151.1K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+1480.2%	+178.1%
Q2 22	+22.4%	-24.5%
Q3 22	+286.0%	-27.9%
Q4 22	-99.9%	-2.4%
Q1 23	-100.0%	+2297.2%
Q2 23	+0.0%	+24.0%
Q3 23	-100.0%	+19.4%
Q1 24	-100.0%	+108.8%
Q2 24	—	-88.9%
Q3 24	-100.0%	+262.6%
Q4 24	—	+220.2%
Q1 25	—	+57.7%
Q2 25	—	+853.5%
Q3 25	—	+303.0%
Q4 25	—	-187.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 21	$3M	202.0%
Q1 22	$4M	1598.4%
Q2 22	$2M	1062.1%
Q3 22	$3M	1138.9%
Q4 22	$2M	311879.4%
Q1 23	$3M	—
Q2 23	$1M	628.3%
Q3 23	$577.9K	—
Q1 24	$8M	—
Q2 24	$11M	—
Q3 24	$19M	—
Q4 24	$11M	—
Q1 25	$11M	—
Q2 25	$479M	—
Q3 25	$0	—
Q4 25	$243M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q3 21	$20M	$6M	—
Q1 22	$21M	$7M	—
Q2 22	$9M	$7M	—
Q3 22	$17M	$6M	—
Q4 22	$5M	$8M	—
Q1 23	$10M	$7M	—
Q2 23	$9M	$6M	—
Q3 23	$15M	$5M	—
Q1 24	$31M	$12M	—
Q2 24	$31M	$14M	—
Q3 24	$38M	$20M	—
Q4 24	$51M	$14M	—
Q1 25	$51M	$16M	—
Q2 25	$208M	$360M	—
Q3 25	$131M	—	$103M
Q4 25	$147M	$78M	—

Revenue Segments

Quarter	License and Service
Q3 21	$1M
Q1 22	$250.0K
Q2 22	$235.0K
Q3 22	$220.0K

Revenue by Geography

Quarter	Latin America
Q3 21	$1M
Q1 22	$250.0K
Q2 22	$235.0K
Q3 22	$220.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$77M	$0	$77M
Q2 22	$57M	$0	$57M
Q3 22	$122M	$0	$122M
Q4 22	$349M	$0	$349M
Q1 23	$71M	$171M	$242M
Q2 23	$42M	$173M	$215M
Q3 23	$24M	$175M	$199M
Q4 23	$71M	$115M	$186M
Q1 24	$61M	$95M	$157M
Q2 24	$29M	$297M	$326M
Q3 24	$94M	$393M	$487M
Q4 24	$105M	$307M	$412M
Q1 25	$212M	$150M	$361M
Q2 25	$298M	$0	$298M
Q3 25	$239M	$0	$239M
Q4 25	$225M	$488M	$713M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 21	99M	+7.5%	—
Q1 22	98M	-0.9%	+169.3%
Q2 22	100M	+1.6%	+20.3%
Q3 22	149M	+49.1%	+61.4%
Q4 22	211M	+42.1%	+113.3%
Q1 23	378M	+79.1%	+285.6%
Q2 23	698M	+84.5%	+600.1%
Q3 23	698M	+0.0%	+369.6%
Q1 24	702M	+0.6%	+232.5%
Q2 24	708M	+0.9%	+87.2%
Q3 24	727M	+2.6%	+4.2%
Q4 24	738M	+1.5%	+5.7%
Q1 25	738M	+0.1%	+5.2%
Q2 25	743M	+0.6%	+4.9%
Q3 25	743M	+0.1%	+2.3%
Q4 25	748M	+0.6%	+1.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 21	$16.6K	79
Q1 22	$2.4K	105
Q2 22	$2.2K	105
Q3 22	$2.1K	105
Q4 22	$9	76
Q1 23	$0	76
Q2 23	$3.1K	76
Q3 23	$0	76
Q1 24	$0	105
Q2 24	$0	105
Q3 24	$0	105
Q4 24	$0	159
Q1 25	$0	159
Q2 25	$0	159
Q3 25	$0	159
Q4 25	$0	265

Revenue / Employee